Following a full submission
AWMSG advice |
|||
| Status: Recommended with restrictions | |||
Desmopressin acetate (Noqdirna®) for the treatment of nocturia due to idiopathic nocturnal polyuria in adults is recommended for restricted use within NHS Wales. Desmopressin acetate (Noqdirna®) should be restricted for use in the following subpopulation within its licensed indication for the treatment of nocturia due to idiopathic nocturnal polyuria in adults:
Desmopressin acetate (Noqdirna®) is not recommended for use within NHS Wales outside of this subpopulation. |
|||
|
|||
Medicine details |
|||
| Medicine name | desmopressin acetate (Noqdirna®) | ||
| Formulation | 25 micrograms, 50 micrograms sublingual tablet | ||
| Reference number | 3282 | ||
| Indication | Treatment of nocturia due to idiopathic nocturnal polyuria in adults |
||
| Company | Ferring Pharmaceuticals (UK) | ||
| BNF chapter | Endocrine system | ||
| Assessment type | Full | ||
| Status | Recommended with restrictions | ||
| Advice number | 1617 | ||
| NMG meeting date | 07/06/2017 | ||
| AWMSG meeting date | 13/09/2017 | ||
| Date of issue | 17/10/2017 | ||
| Date of last review | October 2020 | ||